[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100505230":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":48,"collaborators":50,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":20,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":20,"overallStatus":32,"whyStopped":20,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"deucravacitinib treatment","EXPERIMENTAL","treatment with deucravacitinib for 6 months",[13],"Drug: deucravacitinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","deucravacitinib","Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Raymond Cho, MD, PhD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","415 575 0524","rashes@ucsf.edu",[31],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","San Francisco","California","94115","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-122.41942,37.77493,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":47,"phoneExt":20,"email":29},"Ray Cho, MD, PhD","415-575-0524",{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[51],{"name":52,"class":53},"Bristol-Myers Squibb","INDUSTRY","100505230","phase-4-correction-of-psoriatic-t-cell-signatures-by-deucravacitinib-100505230",false,"NCT05858645","Correction of Psoriatic T Cell Signatures by Deucravacitinib","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Patients with moderate-severe psoriasis (BSA \\>= 10%, PASI \\>=12, static Physician's Global Assessment (sPGA) 3 and above)\n\nExclusion Criteria:\n\n1. taking systemic immunosuppressives in the last 12 weeks\n2. pregnancy\n3. severe immunodeficiency (either from genetic or infectious causes).\n4. tuberculosis or other active serious infection\n5. active systemic malignancy.\n6. breast-feeding\n7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.","ALL","18 Years","75 Years",{"count":64,"type":65},25,"ESTIMATED","INTERVENTIONAL",[68],"PHASE4","This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.",[71],"Psoriasis Vulgaris","2026-06-01",{"date":74,"type":75},"2026-06-04","ACTUAL",{"date":77,"type":75},"2023-10-01",{"date":79,"type":65},"2028-06",{"name":5,"class":6},1]